Is Dr Agarwal's Eye overvalued or undervalued?

As of 4 November 2025, the valuation grade for Dr Agarwal's Eye has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 40.56, an EV to EBITDA of 16.57, and a Price to Book Value of 0.81, which suggests a reasonable valuation compared to its peers.
In comparison to its industry peers, Dr Agarwal's Eye has a PE ratio of 40.56, while Apollo Hospitals, rated as attractive, has a significantly higher PE of 71.4. Other peers like Max Healthcare and Fortis Health are categorized as very expensive with PE ratios of 91.82 and 83.29, respectively. Despite a recent decline in year-to-date stock performance of -13.74%, Dr Agarwal's Eye has outperformed the Sensex over the past three years with a return of 254.76%.